|Trade names||Lotensin, others|
|Defined daily dose||7.5 mg|
|Elimination half-life||10-11 hours|
|Excretion||Kidney and biliary|
|Chemical and physical data|
|Molar mass||424.497 g·mol−1|
|3D model (JSmol)|
Benazepril, sold under the brand name Lotensin among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Versions are available as the combinations benazepril/hydrochlorothiazide and benazepril/amlodipine.
Common side effects include feeling tired, dizziness, cough, and light-headedness with standing. Serious side effects may include kidney problems, low blood pressure, high blood potassium, and angioedema. Use in pregnancy may harm the baby while use when breastfeeding maybe okay. It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity.
Benazepril was patented in 1981 and came into medical use in 1990. It is available as a generic medication. A month supply in the United States costs about US$1.32 as of 2019. In 2017, it was the 104th most commonly prescribed medication in the United States, with more than seven million prescriptions.
It is useful for high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. Other reasonable initial options include angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics.
The most common side effects patients experience are a headache or a chronic cough. The chronic cough develops in about 20% of patients treated, and those patients that experience it find it develops after a few months of use. Anaphylaxis, angioedema, and elevation of potassium levels are more serious side effects that can also occur.
Benazepril should be discontinued during pregnancy, as it can harm the fetus.
Under the brand names Fortekor (Novartis) and VetACE (Jurox Animal Health), benazepril hydrochloride is used to treat congestive heart failure in dogs and chronic kidney failure in cats and dogs.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
- "Benazepril Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- "Benazepril Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Benazepril Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Dykewicz, Mark S. (April 2004). "Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into Mechanisms and Management". Medscape. Retrieved 2 April 2014.
- King JN, Mauron C, Kaiser G (December 1995). "Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs". Am. J. Vet. Res. 56 (12): 1620–8. PMID 8599524.
- O'Grady MR, O'Sullivan ML, Minors SL, Horne R (2009). "Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers". J. Vet. Intern. Med. 23 (5): 977–83. doi:10.1111/j.1939-1676.2009.0346.x. PMID 19572914.